Expression profiling of galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry

American Journal of Pathology

Volumn 173, Issue 6, 2008, Pages 1839-1852

  Mourad Zeidan, Alexandra A ^a   Melnikova, Vladislava O ^a   Wang, Hua ^a   Raz, Avraham ^b   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; COMPLEMENTARY DNA; DIFFERENTIATION SPHINGOLIPID G PROTEIN RECEPTOR 1; EARLY GROWTH RESPONSE FACTOR 1; FIBRONECTIN; FIBRONECTIN 1; GALECTIN 3; GELATINASE A; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 8; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; UVOMORULIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL ULTRASTRUCTURE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DNA FINGERPRINTING; DYSPLASTIC NEVUS; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA CELL; METASTASIS; METASTASIS POTENTIAL; MOLECULAR MIMICRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

EID: 57149104573     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2008.080380     Document Type: Article

References (71)

1. Barondes SH, Castronovo V, Cooper DNW, Cummings RD, Drickamer K, Feizi T, Gitt MA, Hirabayashi J, Hughes C, Kasai K, Leffler H, Liu F-T, Lotan R, Mercurio AM, Monsigny M, Pillai S, Poirer F, Raz A, Rigby PWJ, Rini JM, Wang JL: Galectins: a family of animal beta-galactoside-binding lectins. Cell 1994, 76:597-598
2. Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F: Introduction to galectins. Glycoconj J 2004, 19:433-440
3. Abbott WM, Hounsell EF, Feizi T: Further studies of oligosaccharide recognition by the soluble 13 kDa lectin of bovine heart muscle. Ability to accommodate the blood-group-H and -B-related sequences. Biochem J 1988, 252:283-287
4. Hirabayashi J, Kasai K: The family of metazoan metal-independent beta-galactoside-binding lectins: structure, function and molecular evolution. Glycobiology 1993, 3:297-304
5. Kadrofske MM, Openo KP, Wang JL: The human LGALS3 (galectin-3) gene: determination of the gene structure and functional characterization of the promoter. Arch Biochem Biophys 1998, 349:7-20
6. Gong HC, Honjo Y, Nangia-Makker P, Hogan V, Mazurak N, Bresalier RS, Raz A: The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. Cancer Res 1999, 59:6239-6245
7. Ochieng J, Furtak V, Lukyanov P: Extracellular functions of galectin-3. Glycoconj J 2004, 19:527-535
8. Nakahara S, Oka N, Raz A: On the role of galectin-3 in cancer apoptosis. Apoptosis 2005, 10:267-275
9. Dumic J, Dabelic S, Flogel M: Galectin-3: an open-ended story. Biochim Biophys Acta 2006, 1760:616-635
10. Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A: Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57:5272-5276
11. Matarrese P, Tinari N, Semeraro ML, Natoli C, Iacobelli S, Malorni W: Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett 2000, 473:311-315
12. Oka N, Nakahara S, Takenaka Y, Fukumori T, Hogan V, Kanayama HO, Yanagawa T, Raz A: Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res 2005, 65:7546-7553
13. Lee YJ, Song YK, Song JJ, Siervo-Sassi RR, Kim HR, Li L, Spitz DR, Lokshin A, Kim JH: Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt. Exp Cell Res 2003, 288:21-34
14. Takenaka Y, Fukumori T, Raz A: Galectin-3 and metastasis. Glycoconj J 2004, 19:543-549
15. van den Brule F, Califice S, Castronovo V: Expression of galectins in cancer: a critical review. Glycoconj J 2004, 19:537-542
16. Lahm H, Andre S, Hoeflich A, Kaltner H, Siebert HC, Sordat B, von der Lieth CW, Wolf E, Gabius HJ: Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 2004, 20:227-238
17. Grassadonia A, Tinari N, Iurisci I, Piccolo E, Cumashi A, Innominato P, D'Egidio M, Natoli C, Piantelli M, Iacobelli S: 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj J 2004, 19:551-556
18. Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, Raz A: Metastasis of human colon cancer is altered by modifying expression of the beta-galactoside-binding protein galectin 3. Gastroenterology 1998, 115:287-296
19. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, Honjo Y, Yamamoto Y, Raz A, Kubo T: Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003, 195:111-119
20. Nakahara S, Raz A: Regulation of cancer-related gene expression by galectin-3 and the molecular mechanism of its nuclear import pathway. Cancer Metastasis Rev 2007, 26:605-610
21. Mazurek N, Sun YJ, Price JE, Ramdas L, Schober W, Nangia-Makker P, Byrd JC, Raz A, Bresalier RS: Phosphorylation of galectin-3 contributes to malignant transformation of human epithelial cells via modulation of unique sets of genes. Cancer Res 2005, 65:10767-10775
22. Patterson RJ, Wang W, Wang JL: Understanding the biochemical activities of galectin-1 and galectin-3 in the nucleus. Glycoconj J 2004, 19:499-506
23. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M: Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 2006, 12:6709-6715
24. Sharma N, Seftor RE, Seftor EA, Gruman LM, Heidger PM, Jr., Cohen MB, Lubaroff DM, Hendrix MJ: Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate 2002, 50:189-201
25. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, Konishi F: Vasculogenic mimicry and pseudo-comedo formation in breast cancer. Int J Cancer 2002, 99:821-828
26. Folberg R, Rummelt V, Parys-Van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM: The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993, 100:1389-1398
27. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, Trent JM, Meltzer PS, Hendrix MJ: Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999, 155:739-752
28. Liu C, Huang H, Donate F, Dickinson C, Santucci R, El-Sheikh A, Vessella R, Edgington TS: Prostate-specific membrane antigen directed selective thrombotic infarction of tumors. Cancer Res 2002, 62:5470-5475
29. Passalidou E, Trivella M, Singh N, Ferguson M, Hu J, Cesario A, Granone P, Nicholson AG, Goldstraw P, Ratcliffe C, Tetlow M, Leigh I, Harris AL, Gatter KC, Pezzella F: Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002, 86:244-249
30. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ: The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 2002, 1:661-664
31. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE: Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci USA 2001, 98:8018-8023
32. Hess AR, Seftor EA, Gardner LM, Carles-Kinch K, Schneider GB, Seftor RE, Kinch MS, Hendrix MJ: Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res 2001, 61:3250-3255
33. Hess AR, Seftor EA, Seftor RE, Hendrix MJ: Phosphoinositide 3-kinase regulates membrane Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res 2003, 63:4757-4762
34. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor RE, Nickoloff BJ, Hendrix MJ: Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Res 2005, 65:9851-9860
35. Hess AR, Hendrix MJ: Focal adhesion kinase signaling and the aggressive melanoma phenotype. Cell Cycle 2006, 5:478-480
36. Hess AR, Margaryan NV, Seftor EA, Hendrix MJ: Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: role of the Eph receptors. Dev Dyn 2007, 236:3283-3296
37. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984, 44:3522-3529
38. Zhang RD, Price JE, Schackert G, Itoh K, Fidler IJ: Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications for prognosis. Cancer Res 1991, 51:2029-2035
39. Ishikawa M, Dennis JW, Man S, Kerbel RS: Isolation and characterization of spontaneous wheat germ agglutinin-resistant human melanoma mutants displaying remarkably different metastatic profiles in nude mice. Cancer Res 1988, 48:665-670
40. Fukushima S, Friedell GH, Jacobs JB, Cohen SM: Effect of L-tryptophan and sodium saccharin on urinary tract carcinogenesis initiated by N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. Cancer Res 1981, 41:3100-3103
41. Welch DR, Chen P, Miele ME, McGary CT, Bower JM, Stanbridge EJ, Weissman BE: Microcell-mediated transfer of chromosome 6 into metastatic human C8161 melanoma cells suppresses metastasis but does not inhibit tumorigenicity. Oncogene 1994, 9:255-262
42. Melnikova VO, Mourad-Zeidan AA, Lev DC, Bar-Eli M: Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J Biol Chem 2006, 281:2911-2922
43. Wiznerowicz M, Trono D: Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J Virol 2003, 77:8957-8961
44. Huang S, DeGuzman A, Bucana CD, Fidler IJ: Level of interleukin-8 expression by metastatic human melanoma cells directly correlates with constitutive NF-kappaB activity. Cytokines Cell Mol Ther 2000, 6:9-17
45. Hendrix MJ, Seftor EA, Hess AR, Seftor RE: Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003, 3:411-421
46. van der Schaft DW, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y, Griffioen AW, Hendrix MJ: Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst 2004, 96:1473-1477
47. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor RE, Nakajima M, Hendrix MJ: Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 1991, 47:227-237
48. Breviario F, Caveda L, Corada M, Martin-Padura I, Navarro P, Golay J, Introna M, Gulino D, Lampugnani MG, Dejana E: Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin. Arterioscler Thromb Vasc Biol 1995, 15:1229-1239
49. Lampugnani MG, Resnati M, Raiteri M, Pigott R, Pisacane A, Houen G, Ruco LP, Dejana E: A novel endothelial-specific membrane protein is a marker of cell-cell contacts. J Cell Biol 1992, 118:1511-1522
50. Carmeliet P, Lampugnani MG, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oostuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert JM, Collen D, Dejana E: Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 98:147-157
51. Gory-Faure S, Prandini MH, Pointu H, Roullot V, Pignot-Paintrand I, Vernet M, Huber P: Role of vascular endothelial-cadherin in vascular morphogenesis. Development 1999, 126:2093-2102
52. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor RE, Hendrix MJ: VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther 2006, 5:228-233
53. Singh RK, Gutman M, Radinsky R, Bucana CD, Fidler IJ: Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res 1994, 54:3242-3247
54. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M: Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997, 17:4015-4023
55. Westphal JR, Van't Hullenaar R, Peek R, Willems RW, Crickard K, Crickard U, Askaa J, Clemmensen I, Ruiter DJ, De Waal RM: Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF, and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000, 86:768-776
56. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258:1798-1801
57. Melnikova VO, Bar-Eli M: Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8. Pigment Cell Res 2006, 19:395-405
58. Luca M, Huang S, Gershenwald JE, Singh RK, Reich R, Bar-Eli M: Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol 1997, 151:1105-1113
59. Liu C, Calogero A, Ragona G, Adamson E, Mercola D: EGR-1, the reluctant suppression factor: eGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Crit Rev Oncog 1996, 7:101-125
60. Milbrandt J: A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. Science 1987, 238:797-799
61. Silverman ES, Collins T: Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol 1999, 154:665-670
62. Calogero A, Arcella A, De Gregorio G, Porcellini A, Mercola D, Liu C, Lombari V, Zani M, Giannini G, Gagliardi FM, Caruso R, Gulino A, Frati L, Ragona G: The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas. Clin Cancer Res 2001, 7:2788-2796
63. Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D, Adamson ED: Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997, 72:102-109
64. Liu C, Yao J, Mercola D, Adamson E: The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000, 275:20315-20323
65. Glukhova MA, Thiery JP: Fibronectin and integrins in development. Semin Cancer Biol 1993, 4:241-249
66. Nierodzik ML, Klepfish A, Karpatkin S: Role of platelets, thrombin, integrin IIb-IIIa, fibronectin, and von Willebrand factor on tumor adhesion in vitro and metastasis in vivo. Thromb Haemost 1995, 74:282-290
67. Ruoslahti E: Fibronectin and its alpha 5 beta 1 integrin receptor in malignancy. Invasion Metastasis 1994, 14:87-97
68. Saba TM, Blumenstock FA, Weber P, Kaplan JE: Physiologic role of cold-insoluble globulin in systemic host defense: implications of its characterization as the opsonic alpha 2-surface-binding glycoprotein. Ann NY Acad Sci 1978, 312:43-55
69. Hla T, Maciag T: An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 1990, 265:9308-9313
70. Lee MJ, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, Spiegel S, Hla T: Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998, 279:1552-1555
71. Singleton PA, Dudek SM, Ma SF, Garcia JG: Transactivation of sphingosine 1-phosphate receptors is essential for vascular barrier regulation. Novel role for hyaluronan and CD44 receptor family. J Biol Chem 2006, 281:34381-34393